Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced presentations at the 63rd Annual Meeting of… read more.
Intra-Cellular Therapies, Inc. announced positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg for the prevention of relapse in adult patients with schizophrenia…. read more.
Intra-Cellular Therapies, Inc. announced data presentations at the American College of Neuropsychopharmacology (ACNP) 62nd Annual Meeting . Poster M91 : “Lumateperone in the Treatment of Patients With Major… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
